Literature DB >> 24821328

Beyond intestinal soap--bile acids in metabolic control.

Folkert Kuipers1, Vincent W Bloks1, Albert K Groen1.   

Abstract

Over the past decade, it has become apparent that bile acids are involved in a host of activities beyond their classic functions in bile formation and fat absorption. The identification of the farnesoid X receptor (FXR) as a nuclear receptor directly activated by bile acids and the discovery that bile acids are also ligands for the membrane-bound, G-protein coupled bile acid receptor 1 (also known as TGR5) have opened new avenues of research. Both FXR and TGR5 regulate various elements of glucose, lipid and energy metabolism. Consequently, a picture has emerged of bile acids acting as modulators of (postprandial) metabolism. Therefore, strategies that interfere with either bile acid metabolism or signalling cascades mediated by bile acids may represent novel therapeutic approaches for metabolic diseases. Synthetic modulators of FXR have been designed and tested, primarily in animal models. Furthermore, the use of bile acid sequestrants to reduce plasma cholesterol levels has unexpected benefits. For example, treatment of patients with type 2 diabetes mellitus (T2DM) with sequestrants causes substantial reductions in plasma levels of glucose and HbA1c. This Review aims to provide an overview of the molecular mechanisms by which bile acids modulate glucose and energy metabolism, particularly focusing on the glucose-lowering actions of bile acid sequestrants in insulin resistant states and T2DM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821328     DOI: 10.1038/nrendo.2014.60

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  138 in total

1.  Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome.

Authors:  Burcu Barutcuoglu; Gunes Basol; Yasemin Cakir; Sevki Cetinkalp; Zuhal Parildar; Ceyda Kabaroglu; Dilek Ozmen; Isil Mutaf; Oya Bayindir
Journal:  Ann Clin Lab Sci       Date:  2011       Impact factor: 1.256

Review 2.  Roles of FGF19 in liver metabolism.

Authors:  S Kir; S A Kliewer; D J Mangelsdorf
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2011-08-03

Review 3.  Regulation of canalicular transport activities.

Authors:  R P Oude Elferink; C M Frijters; C Paulusma; A K Groen
Journal:  J Hepatol       Date:  1996       Impact factor: 25.083

4.  Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.

Authors:  C Beysen; E J Murphy; K Deines; M Chan; E Tsang; A Glass; S M Turner; J Protasio; T Riiff; M K Hellerstein
Journal:  Diabetologia       Date:  2011-12-02       Impact factor: 10.122

Review 5.  Perspective: TGR5 (Gpbar-1) in liver physiology and disease.

Authors:  Verena Keitel; Dieter Häussinger
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-04-18       Impact factor: 2.947

Review 6.  Pleiotropic roles of bile acids in metabolism.

Authors:  Thomas Q de Aguiar Vallim; Elizabeth J Tarling; Peter A Edwards
Journal:  Cell Metab       Date:  2013-04-18       Impact factor: 27.287

7.  Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.

Authors:  Quan Shang; Monica Saumoy; Jens Juul Holst; Gerald Salen; Guorong Xu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-12-31       Impact factor: 4.052

8.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

9.  Lipid composition of bile in diabetics and obesity-matched controls.

Authors:  G B Haber; K W Heaton
Journal:  Gut       Date:  1979-06       Impact factor: 23.059

10.  Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.

Authors:  Reid M Huber; Kathleen Murphy; Bowman Miao; John R Link; Mark R Cunningham; Mark J Rupar; Paul L Gunyuzlu; Thomas F Haws; Altaf Kassam; Francoise Powell; Gregory F Hollis; Peter R Young; Ranjan Mukherjee; Timothy C Burn
Journal:  Gene       Date:  2002-05-15       Impact factor: 3.688

View more
  161 in total

1.  Increased glycine-amidated hyocholic acid correlates to improved early weight loss after sleeve gastrectomy.

Authors:  Tammy L Kindel; Crystal Krause; Melissa C Helm; Corrigan L McBride; Dmitry Oleynikov; Rhishikesh Thakare; Jawaher Alamoudi; Vishal Kothari; Yazen Alnouti; Rohit Kohli
Journal:  Surg Endosc       Date:  2017-08-04       Impact factor: 4.584

2.  Gut microbiota: Ganoderma lucidum, a new prebiotic agent to treat obesity?

Authors:  Nathalie M Delzenne; Laure B Bindels
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-08-18       Impact factor: 46.802

3.  The effects of time-restricted feeding on lipid metabolism and adiposity.

Authors:  Amandine Chaix; Amir Zarrinpar
Journal:  Adipocyte       Date:  2015-04-20       Impact factor: 4.534

4.  Chemical synthesis of 7-oxygenated 12α-hydroxy steroid derivatives to enable the biochemical characterization of cytochrome P450 8B1, the oxysterol 12α-hydroxylase enzyme implicated in cardiovascular health and obesity.

Authors:  Samuel D Offei; Hadi D Arman; Mirza Oais Baig; Lazaro S Chavez; Carlos A Paladini; Francis K Yoshimoto
Journal:  Steroids       Date:  2018-11-03       Impact factor: 2.668

5.  Quantification of common and planar bile acids in tissues and cultured cells.

Authors:  Stephanie J Shiffka; Jace W Jones; Linhao Li; Ann M Farese; Thomas J MacVittie; Hongbing Wang; Peter W Swaan; Maureen A Kane
Journal:  J Lipid Res       Date:  2020-07-22       Impact factor: 5.922

6.  Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Seema Singh; Shirin Bassirian; James Kolar; Claire Faulkner; Nikhil Sinha; Ricki Bettencourt; Naveen Gara; Mark A Valasek; Bernd Schnabl; Lisa Richards; David A Brenner; Alan F Hofmann; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2018-12-02       Impact factor: 8.171

Review 7.  Cholecystectomy and risk of metabolic syndrome.

Authors:  Agostino Di Ciaula; Gabriella Garruti; David Q-H Wang; Piero Portincasa
Journal:  Eur J Intern Med       Date:  2018-04-26       Impact factor: 4.487

8.  Host Genotype and Gut Microbiome Modulate Insulin Secretion and Diet-Induced Metabolic Phenotypes.

Authors:  Julia H Kreznar; Mark P Keller; Lindsay L Traeger; Mary E Rabaglia; Kathryn L Schueler; Donald S Stapleton; Wen Zhao; Eugenio I Vivas; Brian S Yandell; Aimee Teo Broman; Bruno Hagenbuch; Alan D Attie; Federico E Rey
Journal:  Cell Rep       Date:  2017-02-14       Impact factor: 9.423

9.  The association between gut microbiota development and maturation of intestinal bile acid metabolism in the first 3 y of healthy Japanese infants.

Authors:  Masaru Tanaka; Masafumi Sanefuji; Seiichi Morokuma; Misako Yoden; Rie Momoda; Kenji Sonomoto; Masanobu Ogawa; Kiyoko Kato; Jiro Nakayama
Journal:  Gut Microbes       Date:  2019-09-24

Review 10.  Microbial modulation of cardiovascular disease.

Authors:  J Mark Brown; Stanley L Hazen
Journal:  Nat Rev Microbiol       Date:  2018-01-08       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.